- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04447768
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
A Phase II: Venetoclax-Based Therapy for the Treatment of Fit Patients With Chronic Lymphocytic Leukemia (CLL) in the Front-Line Setting
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Lindsey Roeker, MD
- Phone Number: 646-608-4115
- Email: roekerl@mskcc.org
Study Contact Backup
- Name: Jae Park, MD
- Phone Number: 646-608-3743
Study Locations
-
-
California
-
Stanford, California, United States, 94305-5408
- Recruiting
- Stanford University Medical Center (Data collection only)
-
Contact:
- Bita Fakhri, MD
- Phone Number: 650-498-6000
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Recruiting
- Memorial Sloan Kettering Basking Ridge (All protocol activities)
-
Contact:
- Lindsey Roeker, MD
- Phone Number: 646-608-4115
-
Middletown, New Jersey, United States, 07748
- Recruiting
- Memorial Sloan Kettering Monmouth (All Protocol Activities)
-
Contact:
- Lindsey Roeker, MD
- Phone Number: 646-608-4115
-
-
New York
-
Commack, New York, United States, 11725
- Recruiting
- Memorial Sloan Kettering Commack (All protocol activities)
-
Contact:
- Lindsey Roeker, MD
- Phone Number: 646-608-4115
-
Harrison, New York, United States, 10604
- Recruiting
- Memorial Sloan Kettering Westchester (All protocol activities)
-
Contact:
- Lindsey Roeker, MD
- Phone Number: 646-608-4115
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
Contact:
- Lindsey Roeker, MD
- Phone Number: 646-608-4115
-
Uniondale, New York, United States, 11553
- Recruiting
- Memorial Sloan Kettering Nassau (All protocol activities)
-
Contact:
- Lindsey Roeker, MD
- Phone Number: 646-608-4115
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- Recruiting
- University of North Carolina
-
Contact:
- Catherine Coombs, MD
- Phone Number: 984-974-0000
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed informed consent form.
- Ability and willingness to comply with the requirements of the study protocol.
- Age ≥18 years.
- Have documented previously untreated chronic lymphocytic leukemia according to iwCLL / WHO criteria.
- Require treatment of CLL per iwCLL guidelines.
- CIRS score ≤ 6 (patient's CLL diagnosis is not included in CIRS score).
- Eastern Cooperative Oncology Group Performance Status of 0 or 1.
Adequate hematologic function (unless caused by underlying disease, as established by extensive bone marrow involvement or as a result of hypersplenism secondary to the involvement of the spleen by CLL per the investigator) defined as follows:
- Hemoglobin ≥ 8 g/dL without transfusion support, unless anemia is due to marrow involvement of CLL.
- Absolute neutrophil count ≥ 1.0 x 10^9/L.
- Platelet count ≥ 30 x 10^9/L; in cases of thrombocytopenia clearly due to marrow involvement of CLL (per the discretion of the investigator), platelet count should be ≥ 10 x 10^9/L if there is bone marrow involvement.
- Adequate renal function, as indicated by modified Cockcroft-Gault equation (eCCR; with the use of ideal body mass [IBM] instead of mass) of > 50mL/min
Adequate liver function, as indicated by:
- AST or ALT ≤ 2.5 x ULN.
- Total bilirubin ≤ 1.5 x ULN (or ≤ 5 x ULN for patients with documented Gilbert syndrome).
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 30 days after the last dose of venetoclax or 18 months after the last dose of obinutuzumab, whichever is longer.
- Women must refrain from donating eggs during this same period.
- A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (> 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).
- Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
- The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:
- With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 90 days after the last dose of venetoclax or 18 months after the last dose of obinutuzumab, whichever is longer. Men must refrain from donating sperm during this same period.
- With pregnant female partners, men must remain abstinent or use a condom for the duration of the pregnancy to avoid exposing the embryo.
- The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
Exclusion Criteria:
- Prior CLL-directed therapy. Patients may have received a brief (≤7 days) course of systemic steroids prior to initiation of study therapy for control of lymphoma-related symptoms.
- Transformation of CLL to aggressive NHL (Richter's transformation or prolymphocytic leukemia).
- Known hypersensitivity to any of the study drugs.
History of prior malignancy, except for conditions as listed below if patients have recovered from the acute side effects incurred as a result of previous therapy:
- Malignancies treated with curative intent and with no known active disease within 2 years
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease (no time constraint).
- Adequately treated cervical carcinoma in situ without evidence of disease (no time constraint).
- Surgically/adequately treated low grade, early stage, localized prostate cancer without evidence of disease (no time constraint).
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day 1.
- Requires the use of warfarin (because of potential drug-drug interactions that may potentially increase the exposure of warfarin).
Received the following agents within 7 days prior to the first dose of venetoclax:
- Strong and moderate CYP3A inhibitors.
- Strong and moderate CYP3A inducers.
- Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax.
- Clinically significant history of liver disease, including active viral or other hepatitis, current alcohol abuse, or cirrhosis
Presence of positive test results for hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg), or hepatitis C (HCV) antibody
- Patients who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation
- Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing and should consider antiviral prophylaxis as per institutional standards.
- Known infection with HIV or human T-cell leukemia virus 1 (HTLV-1)
- Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
Pregnant or lactating, or intending to become pregnant during the study
°Women of childbearing potential must have a negative serum pregnancy test result within 21 days prior to initiation of study drug per institutional standards.
- Recent major surgery (within 4 weeks prior to the start of Cycle 1, Day 1) other than for diagnosis.
- Inability to swallow a large number of tablets.
- Malabsorption syndrome or other condition that precludes enteral route of administration. This is subject to investigator discretion.
- Known allergy to both xanthine oxidase inhibitors and rasburicase.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Venetoclax and Obinutuzumab
All patients will receive a minimum of 9 cycles (cycle = 28 days) of therapy with venetoclax and obinutuzumab during the treatment period.
For patients who remain MRD positive at Cycle 9 of therapy, an additional 12 cycles of venetoclax monotherapy will be given.
|
Cycle 1, Day 1- 100 mg Cycle 1, Day 2 - 900 mg Cycle 1, Day 8 - 1000 mg Cycle 1, Day 15 -1000 mg Cycle 2, Day 1 to Cycle 6, Day 1- 1000 mg Cycle 1, Day 22 to 28 -20 mg daily Cycle 2, Day 1 to Day 7 -50 mg daily Cycle 2, Day 8 to Day 14- 100 mg daily Cycle 2, Day 15 to Day 21- 200 mg daily Cycle 2, Day 22 to Day 28 - 400 mg daily Cycle 3, Day 1 to end of Cycle 12-24 - 400 mg daily |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
progression-free survival (PFS)
Time Frame: 36 months
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate
Time Frame: 2 years
|
Overall response rate (ORR) is defined as the proportion of patients with a best overall response of partial response (PR) or complete response (CR).
Patients who do not have a tumor response assessment for any reason will be considered non-responders and will be included in the denominator when calculating the ORR.
|
2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Lindsey Roeker, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Leukemia, B-Cell
- Chronic Disease
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Venetoclax
- Obinutuzumab
Other Study ID Numbers
- 20-044
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lymphocytic Leukemia (CLL)
-
AbbVieRecruitingCancer, Chronic Lymphocytic Leukemia (CLL)Korea, Republic of
-
Hackensack Meridian HealthCelgene CorporationTerminatedSmall Lymphocytic Lymphoma | Chronic Lymphocytic Leukemia(CLL)United States
-
Piramal Enterprises LimitedDana-Farber Cancer Institute; Norris Cotton Cancer CenterSuspendedRelapsed/Refractory Chronic Lymphocytic Leukemia (CLL)United States
-
Tampere University HospitalCompleted
-
Virginia Commonwealth UniversityGilead SciencesWithdrawnChronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma
-
AstraZenecaRecruitingChronic Lymphocytic Leukaemia (CLL)Germany
-
University of California, IrvineUnited States Department of DefenseActive, not recruitingAcute Myeloid Leukemia | Chronic Lymphocytic Leukemia | AML, Adult | CLL | CLL, Relapsed | CLL, RefractoryUnited States
-
Memorial Sloan Kettering Cancer CenterPharmacyclics LLC.WithdrawnChronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | CLL/SLL | SLLUnited States
-
Novartis PharmaceuticalsCompletedChronic Lymphocytic Leukemia (CLL) | Leukaemia, Lymphocytic, ChronicUnited States, Belgium, Italy, Greece, Russian Federation, Spain, Poland, Czech Republic
-
AstraZenecaCLL ConsortiumCompletedB Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)United States
Clinical Trials on Obinutuzumab
-
Institute of Hematology & Blood Diseases Hospital...RecruitingImmune Thrombocytopenia | TreatmentChina
-
Qianfoshan HospitalNot yet recruitingIdiopathic Membranous Nephropathy
-
Michael ChoiPharmacyclics LLC.Withdrawn
-
Institute of Hematology & Blood Diseases HospitalRecruitingImmune Thrombocytopenia | TreatmentChina
-
Hoffmann-La RocheCompletedFollicular Lymphoma | Chronic Lymphocytic LeukemiaKorea, Republic of
-
French Innovative Leukemia OrganisationHoffmann-La RocheNot yet recruiting
-
The First Affiliated Hospital with Nanjing Medical...RecruitingObinutuzumab | Rapid Infusion | Intravenous Infusion ReactionChina
-
Fondazione Italiana Linfomi - ETSRoche Pharma AGRecruiting
-
TG Therapeutics, Inc.CompletedChronic Lymphocytic LeukemiaUnited States
-
Paolo GhiaRecruitingChronic Lymphocytic LeukemiaItaly